0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-85.03%PremiumDec 20, 2024Expiry Date14.21Intrinsic Value100Multiplier43DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pieris Pharmaceuticals Stock Discussion
3 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
Ongoing Phase 3 trial evaluating QTORIN™ 3.9% rapamycin...
PRNewswire 24-Jul-2024 2:55 PM
This firm never misses a merger! Dont know if they do good work on not but Damn! Its every one! Hehehe
$Pieris Pharmaceuticals (PIRS.US)$
No comment yet